COPD exacerbation

1. History

• Key HPI questions: Onset and duration of worsening dyspnea, cough, sputum volume and color (especially purulence), wheeze, chest tightness
• Symptom characterization: Quantify dyspnea severity (VAS 0–10); compare to baseline functional status; ask about exercise tolerance and ability to perform ADLs [1]
• Timing/triggers: Recent URI, sick contacts, cold/heat exposure, air pollution, wildfire smoke, medication non-adherence, recent steroid taper [3]
• Progression: Gradual over days (typical AECOPD) vs. sudden onset (consider PE, pneumothorax)
• Associated symptoms: Fever, hemoptysis, chest pain, leg swelling, orthopnea, weight gain
• Important negatives: No pleuritic chest pain, no unilateral leg swelling, no syncope, no recent immobilization/surgery

2. Alarm Features

• Dyspnea or tachypnea at rest unrelieved by bronchodilators [4]
• Altered mental status (confusion, somnolence — suggests hypercapnia/ventilatory failure) [3]
• Accessory muscle use, tripoding, inability to speak in full sentences
• SpO₂ <88%, cyanosis
• Hemodynamic instability (hypotension, tachycardia >120 bpm)
• New-onset chest pain or hemoptysis (consider PE, MI, pneumothorax)
• Fever with localized chest findings (pneumonia) [4]
• Increasing lower-extremity edema (acute heart failure, cor pulmonale)

3. Medications

Acute treatment (the "Big 3"): [3][5]

• Bronchodilators: Albuterol 2.5 mg nebulized q20 min × 3, then q1–4h; add ipratropium 0.5 mg nebulized if limited response. MDI with spacer is equally effective in less sick patients [3]
• Systemic corticosteroids: Prednisone 40 mg PO daily × 5 days (equally effective as longer courses, with fewer side effects) [3][5]
• Antibiotics (when indicated): 5-day course — first-line: amoxicillin/clavulanate, azithromycin, or doxycycline; reserve fluoroquinolones for repeated exacerbations or suspected resistance [4][6-7]

4. Diet

• Acute phase: Small, frequent meals to reduce diaphragmatic splinting; avoid large meals that worsen dyspnea
• Hydration: Adequate hydration to thin secretions (unless fluid-restricted for heart failure)
• Long-term: Mediterranean-style diets rich in antioxidants, fruits, vegetables, and fiber are associated with better lung health outcomes [9]
• Nutritional status: Malnutrition is common in advanced COPD and is an independent risk factor for poor outcomes; assess BMI and consider nutritional supplementation [10]

5. Review of Systems

• Pulmonary: Dyspnea severity, cough character, sputum volume/color, wheeze, hemoptysis
• Cardiovascular: Chest pain, palpitations, orthopnea, PND, leg edema (heart failure, PE, MI are common mimics) [3]
• Infectious: Fever, chills, myalgias, recent URI symptoms
• Psychiatric: Anxiety, panic (can mimic or worsen dyspnea); depression (common comorbidity)
• GI: GERD symptoms (risk factor for exacerbations) [3]
• Musculoskeletal: Deconditioning, muscle wasting

6. Collateral History and Family History

• Collateral: Baseline functional status, home oxygen use, prior intubations/ICU admissions, medication adherence, inhaler technique, caregiver support at home
• Family history: Alpha-1 antitrypsin deficiency (especially if early-onset COPD or minimal smoking history)
• Social context: Smoking status (current vs. former, pack-years), biomass fuel exposure, occupational exposures, housing conditions (mold, pollution), ability to access medications and follow-up

7. Risk Factors

• Strongest predictor: History of prior exacerbations (≥2/year defines the "frequent exacerbator" phenotype) [3][11]
• Severe airflow limitation (low FEV₁) [3]
• Active smoking or ongoing pollutant exposure [3]
• Comorbidities: heart failure, coronary artery disease, GERD, anxiety/depression, bronchiectasis [2-3]
• Poor nutritional status, low BMI [10]
• Female sex [12]
• Winter season, cold temperatures, influenza circulation [3][12]
• Non-adherence to maintenance inhalers
• Elevated blood eosinophils (associated with steroid-responsive exacerbations) [3]

8. Differential Diagnosis

Per the 2026 GOLD guidelines, the following conditions can mimic or worsen AECOPD and must be systematically excluded: [2-3]

9. Past Medical History

• Prior COPD diagnosis, baseline FEV₁, GOLD stage
• Prior exacerbation frequency (most important predictor of future events) [3]
• History of intubation or ICU admission
• Home oxygen use, home NIV/CPAP
• Comorbidities: CHF, CAD, atrial fibrillation, diabetes, CKD, OSA, bronchiectasis
• Vaccination status: influenza, pneumococcal, COVID-19, RSV
• Surgical history: prior lung surgery, lung volume reduction

10. Physical Exam

11. Lab Studies

Recommended in ED/hospital setting: [1][14-15]

• ABG/VBG: Assess for hypoxemia (PaO₂ ≤60 mmHg), hypercapnia (PaCO₂ >45 mmHg), and acidosis (pH <7.35) — gold standard for severity classification [3]
• CBC: Leukocytosis (infection), eosinophilia (may guide steroid use), anemia
• BMP: Electrolytes, renal function (BUN ≥25 is a BAP-65 risk factor)
• CRP: Recommended by GOLD; CRP ≥10 mg/L suggests moderate/severe exacerbation; CRP >11.5 mg/L has 91% sensitivity for consolidation on CT [1][16]
• BNP/NT-proBNP: Rule out heart failure as mimic or co-contributor [3]
• Troponin: If ACS or PE suspected [3]
• D-dimer: If PE is clinically suspected
• Procalcitonin: May help guide antibiotic decisions (bacterial vs. viral)
• Blood eosinophils: Emerging role in guiding corticosteroid therapy [3]
• Sputum culture: Not routinely useful due to chronic colonization; consider in severe exacerbations or treatment failure [4]

12. Imaging

• Chest X-ray (first-line): Obtain in all moderate/severe exacerbations to rule out pneumonia, pneumothorax, pleural effusion, pulmonary edema [3][15]
  • [13]
• CT chest: Not routine; indicated if concern for PE (CTA), suspected malignancy, or recurrent exacerbations (evaluate for bronchiectasis, emphysema) [3]
• Point-of-care ultrasound: Useful for rapid assessment of pneumothorax, pleural effusion, B-lines (pulmonary edema), cardiac function, and IVC [14]
• Imaging unnecessary: Mild exacerbations managed in the outpatient setting with clear clinical picture

13. Special Tests

• BAP-65 Score: Risk-stratifies in-hospital mortality and need for mechanical ventilation in AECOPD patients >40 years (uses BUN, altered mental status, pulse, and age)[supported calculator]
• Rome Severity Classification: Uses dyspnea VAS, RR, HR, SpO₂, CRP, and ABG to classify mild/moderate/severe [1][3]
• GOLD COPD Criteria: For stable-state classification (not during acute exacerbation) to guide long-term therapy[supported calculator]
• End-tidal CO₂ (ETCO₂): Waveform analysis can help assess bronchospasm severity and CO₂ retention [14]
• Viral respiratory panel: Nasal swab to identify viral triggers (rhinovirus, influenza, RSV) [3]

14. ECG

• Indications: Obtain in all moderate/severe exacerbations presenting to the ED [15]
• Expected findings: Sinus tachycardia, right axis deviation, P-pulmonale (peaked P waves in II, III, aVF), low voltage, poor R-wave progression
• Dangerous patterns to recognize:
  • Atrial fibrillation/flutter — common comorbidity and exacerbation mimic [3]
  • Right heart strain (S1Q3T3, RBBB, RV strain pattern) → consider PE
  • ST changes/T-wave inversions → ACS
  • Multifocal atrial tachycardia (MAT) — classically associated with severe COPD/cor pulmonale

15. Assessment

Severity stratification (Rome Classification): [3]

• Typical presentation: Gradual worsening of dyspnea, cough, and sputum over days with diffuse wheezing
• Atypical presentations: Isolated confusion in elderly (hypercapnia), chest pain (consider PE/ACS), isolated edema (cor pulmonale/CHF)
• Complications: Respiratory failure, pneumothorax, arrhythmia, VTE, secondary pneumonia, death
• Approximately 25% die within 1 year and 65% within 5 years of hospitalization for AECOPD [2]

16. Treatment Plan

17. Disposition

Admission criteria: [3-4]

• New or worsening hypoxemia or hypercapnia
• Persistent dyspnea/tachypnea after initial bronchodilator and steroid therapy
• Respiratory acidosis (pH <7.35)
• Altered mental status
• Accessory muscle use, overt respiratory distress
• Need for NIV or mechanical ventilation
• Significant comorbidities (heart failure, arrhythmia)
• Inadequate home support, frailty, elderly

18. Follow Up / Return Precautions

Follow-up timing: [3-4]

• Early follow-up: <4 weeks post-discharge (reduces readmission risk)
• Late follow-up: 12–16 weeks — spirometry, reassess symptoms (CAT/mMRC), oxygen needs, comorbidities
• Contact within 48 hours of ED discharge to verify stability [4]

At discharge, ensure: [3][18]

• Review and optimize maintenance therapy (LABA + LAMA ± ICS based on eosinophils and exacerbation history)
• Reassess inhaler technique
• Smoking cessation counseling
• Vaccination status (influenza, pneumococcal, COVID-19, RSV)
• Pulmonary rehabilitation referral (ideally within 3 weeks)
• Provide written action plan

Return precautions — instruct patients to seek immediate care for:

• Worsening shortness of breath not relieved by rescue inhaler
• Confusion, excessive drowsiness
• Fever >101°F (38.3°C)
• Chest pain
• Coughing up blood
• New or worsening leg swelling

Expected recovery: 4–6 weeks; up to 20% of patients do not return to pre-exacerbation baseline. [3] Readmission rates are 30–50% within 30 days, making close follow-up critical. [3]